For Q1 FY2026 (ended March 31, 2026), Neurocrine Biosciences reported revenue of $814.5 million, up 42.2% year-over-year. Net income surged to $197.9 million from $7.9 million in the prior year quarter, while diluted EPS rose to $1.91 from $0.08. Operating income was $193.4 million, a 719.5% increase. The company had $266.5 million in cash and $3.41 billion in equity, with no long-term debt.
•Revenue increased 42.2% YoY to $814.5M.
•Net income rose to $197.9M from $7.9M YoY.
•Diluted EPS grew to $1.91 from $0.08 YoY.
•Operating income increased 719.5% to $193.4M.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Neurocrine Biosciences, Inc. discovers develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and globally.
The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease. Its portfolio also includes Orilissa tablets for endometriosis, Oriahnn capsules to treat uterine fibroids, and CRENESSITY to treat congenital adrenal hyperplasia Offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders.
Its portfolio also includes Osavampator for inadequate response to treatment in major depressive disorder, NBI-1117568 for the treatment of schizophrenia and bipolar mania, NBI-1117567 for the treatment of Alzheimer's disease, NBI 921355 for the treatment of epilepsy, NBIP-01435 for the treatment of congenital adrenal hyperplasia, NBIP-2118 for the treatment of obesity and related metabolic diseases, NBI-1070770 to treat major depressive disorder, and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions.
It also has license and collaboration agreements with Nxera Pharma UK Limited. Its portfolio also includes Takeda Pharmaceutical Company Limited, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., Sanofi S.A., Tanabe Pharma Corporation, and AbbVie Inc. Incorporated in 1992, the company is headquartered in San Diego, California.
Neurocrine Biosciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders. Its lead product is INGREZZA, approved for tardive dyskinesia and chorea associated with Huntington's disease. The company also markets Orilissa for endometriosis, Oriahnn for uterine fibroids, and CRENESSITY for congenital adrenal hyperplasia, as well as ALKINDI and Efmody. Its pipeline includes candidates for major depressive disorder (Osavampator, NBI-1070770), schizophrenia (NBI-1117568), Alzheimer's disease (NBI-1117567), epilepsy (NBI 921355), obesity (NBIP-2118), and various neuropsychiatric conditions. Neurocrine also has collaboration agreements with partners such as Nxera Pharma, Takeda, Xenon Pharmaceuticals, Voyager Therapeutics, Sanofi, Tanabe Pharma, and AbbVie.
Where is Neurocrine Biosciences (NBIX) listed and in what currency?
Neurocrine Biosciences is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol NBIX. Its shares are traded in US dollars (USD). The company is headquartered in San Diego, California, and operates primarily in the United States, though it also has a global presence. As a US-based company listed on a major US exchange, its financial reporting is in USD, making it accessible to investors trading in US markets.
What sector and industry does Neurocrine Biosciences (NBIX) belong to?
Neurocrine Biosciences operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This means the company focuses on developing and manufacturing specialized pharmaceutical products, often for niche or complex conditions, rather than broad-market generic drugs. Its specialty includes treatments for neurological and endocrine disorders, such as tardive dyskinesia, Huntington's disease, endometriosis, and congenital adrenal hyperplasia. The company's pipeline also targets psychiatric and metabolic diseases, aligning with its specialty drug manufacturer classification.
Where is Neurocrine Biosciences (NBIX) headquartered and what markets does it serve?
Neurocrine Biosciences is headquartered in San Diego, California, United States. It was incorporated in 1992. The company serves markets in the United States and globally, with a focus on neurological, psychiatric, endocrine, and immunological disorders. Its commercial products include INGREZZA, Orilissa, Oriahnn, CRENESSITY, ALKINDI, and Efmody, which are available in the US and other countries. The company also has research and development activities and collaborations with international partners such as Nxera Pharma UK Limited, Takeda Pharmaceutical Company Limited (Japan), Xenon Pharmaceuticals Inc. (Canada), Voyager Therapeutics, Inc. (US), Sanofi S.A. (France), Tanabe Pharma Corporation (Japan), and AbbVie Inc. (US), indicating a broad global reach.
How does Neurocrine Biosciences (NBIX) generate revenue?
Neurocrine Biosciences generates revenue primarily through the commercialization of its approved pharmaceutical products. Its key revenue driver is INGREZZA, used for tardive dyskinesia and chorea associated with Huntington's disease. The company also earns from sales of Orilissa (endometriosis), Oriahnn (uterine fibroids), CRENESSITY (congenital adrenal hyperplasia), and other products like ALKINDI and Efmody. Additionally, Neurocrine has license and collaboration agreements with multiple pharmaceutical companies, including Nxera Pharma, Takeda, Xenon, Voyager, Sanofi, Tanabe, and AbbVie, which may provide milestone payments, royalties, or profit-sharing. Its pipeline of drug candidates in clinical development for major depressive disorder, schizophrenia, Alzheimer's disease, epilepsy, obesity, and other conditions represents potential future revenue streams.